e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung function indices for predicting mortality in COPD
Afroditi K. Boutou, Dinesh Shrikrishna, Rebecca J. Tanner, Cayley Smith, Julia L. Kelly, Simon P. Ward, Michael I. Polkey, Nicholas S. Hopkinson
Source:
Eur Respir J 2013; 42: 616-625
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Afroditi K. Boutou, Dinesh Shrikrishna, Rebecca J. Tanner, Cayley Smith, Julia L. Kelly, Simon P. Ward, Michael I. Polkey, Nicholas S. Hopkinson. Lung function indices for predicting mortality in COPD. Eur Respir J 2013; 42: 616-625
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD
Source: Eur Respir J 2013; 42: 606-615
Year: 2013
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations
Source: Eur Respir J 2013; 41: 12-17
Year: 2013
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006
Hemodynamic effects of inhaled fenoterol and ipratropium in patients with obstructive pulmonary diseases
Source: International Congress 2014 – Monitoring airway diseases with lung function tests
Year: 2014
Tiotropium in COPD patients
Source: Breathe 2008; 5: 271
Year: 2009
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD
Source: Eur Respir J 2014; 43: 1818-1819
Year: 2014
Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD
Source: Eur Respir J 2014; 43: 1816-1818
Year: 2014
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Prevention of deteriorations in COPD on stepping up from tiotropium to umeclidinium/vilanterol
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Preference, satisfaction and critical errors with Genuair
®
and Breezhaler
®
in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
COPD and asthma patients are satisfied with handling and inhalation characteristics of Soft Mist InhalerÔ (Berodual® Respimat®)
Source: Eur Respir J 2006; 28: Suppl. 50, 739s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept